With Jeuveau Approval, Evolus Will Focus On The Beauty Business To Gain Market Share
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
You may also be interested in...
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.